Stayble appoints Mangold as Liquidity Provider
Stayble Therapeutics AB (”Stayble” or the “Company”) has appointed Mangold Fondkommission as liquidity provider for the Company's share on Nasdaq First North Growth Market with first day of trading March 9.
A liquidity provider’s aim is to improve the liquidity of a share and reduce the spread between the bidding and asking price. Mangold Fondkommission’s assignment commences on the first day of trading March 9, 2020.
Mangold will fulfill its assignment as liquidity provider to ensure the possibility of trading in Stayble’s share every day by continuously placing trading records on each purchase and sales page in the order book. A liquidity provider aims to create a more accurate pricing of a company's share, which in turn gives a more accurate valuation of the company and allows for an improved trading volume in the share.
For more information
Andreas Gerward, CEO Stayble Therapeutics AB
+46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development of the upcoming clinical phase 2b study. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.
Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail email@example.com